Tags : Advanced Renal Cell Carcinoma

Eisai Reports Results of Lenvima (lenvatinib) + Everolimus in P-II

Shots: The P-II 218 study involves assessing Lenvima (14mg, qd) + everolimus (5mg, qd) vs Lenvima (18mg, qd) + everolimus (5mg qd) in patients with clear-cell RCC, following treatment with an anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permitted In the primary analysis, @24wks. ORR (32.1% vs 34.8%) i.e. lower dose did not meet the threshold […]Read More

Takeda Files NDA for Cabometyx (cabozantinib) to MHLW for Advanced

Shots: The submission is based on METEOR, CABOSUN and Takeda’s bridging study. METEOR & CABOSUN studies result assessing Cabometyx vs everolimus & sunitinib in patients with RCC + prior treated with at least one VEGFR-TKI inhibitor & untreated advanced RCC with intermediate/poor-risk disease respectively In Q2’19, Exelixis is expected to receive $10M as milestones from […]Read More